Syros Pharmaceuticals Inc SYRS has set the world abuzz with its groundbreaking findings from the SELECT-AML-1 Phase 2 trial. The results of the trial have sent the stock soaring to astronomical heights.
The company has reported remarkable initial data from its ongoing trial, revealing the efficacy of tamibarotene in combination with venetoclax and azacitidine in newly diagnosed, unfit patients with acute myeloid leukemia (AML) and RARA gene overexpression.
With an 83% response rate among patients, the trial data clearly demonstrates the potential of the treatment in addressing the needs of AML patients.
As of November 13, 2023, 23 newly diagnosed unfit AML patients positive for RARA overexpression had enrolled in the trial, showcasing the growing interest and potential impact of the treatment.
The exceptional results have led to a 100% CR/CRi rate among response evaluable patients treated with tamibarotene, venetoclax, and azacitidine, setting a new benchmark in the AML treatment landscape.
These findings have electrified the scientific community, with the combination therapy demonstrating a significantly higher CR/CRi rate compared to the control group, marking a watershed moment in AML research and treatment.
The median time to CR/CRi response was 21 days among patients treated with the combination, further emphasizing the rapid and robust response to the treatment, highlighting its potential to bring about quick and effective results in AML patients.
The company’s commitment to pushing the boundaries of medical research is evident as it continues to enroll patients in SELECT-AML-1, with plans to report updated data in 2024, promising further breakthroughs in AML treatment.
Syros is also on track to complete patient enrollment in SELECT-MDS-1 in Q1 of 2024, expecting to report pivotal CR data by mid-Q4 of 2024, further solidifying its position as a trailblazer in the field of oncology.
Also Read: Pfizer To Terminate Development Pact With Syros Pharmaceuticals For Novel Therapies For Two Blood Disorders.
Price Action: SYRS shares are up 46.50% at $4.13 on the last check Wednesday, a testament to the market’s resounding approval of the company’s groundbreaking achievements.